Chongqing Genrix Biopharmaceutical Third Quarter 2024 Earnings: CN¥0.50 loss per share (vs CN¥0.49 loss in 3Q 2023)

Chongqing Genrix Biopharmaceutical (SHSE:688443) Third Quarter 2024 Results

Key Financial Results

• Net loss: CN¥184.4m (loss widened by 2.4% from 3Q 2023).
• CN¥0.50 loss per share (further deteriorated from CN¥0.49 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chongqing Genrix Biopharmaceutical Earnings Insights

Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with Chongqing Genrix Biopharmaceutical.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.